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Survey of congenital heart surgeons' preferences for antimicrobial prophylaxis for 
pediatric cardiac surgery patients 
Chad A. Knoderer, Emily M. Anderson, Emily M. Anderson  
Patients with congenital heart defects are a unique population with generally immature immune 
systems. Fragility in the postoperative period may contribute to surgical site infections (SSIs), a 
life threatening complication for this population. The need for postoperative antimicrobial 
prophylaxis for these patients is a standard of care that is indisputable. When choosing an 
antimicrobial regimen for surgical prophylaxis, consideration should be given to balancing the 
prevention of nosocomial infections, avoiding emergence of bacterial resistance, and minimizing 
drug toxicities and cost.  
Organizations including the American Society of Health-System Pharmacists (ASHP), the 
Society of Thoracic Surgeons (STS), the Surgical Infection Prevention (SIP) project team, the 
Centers for Medicare and Medicaid Services, and the U.S. Centers for Disease Control and 
Prevention have developed guidelines for the selection, initiation, and duration of antibiotic use 
in patients perioperatively (table).1-4 Only ASHP recommendations specifically address surgical 
prophylaxis for children undergoing cardiac surgery, although not in extensive detail and with 
much extrapolation of data from adult studies. (1)  
In November 2006, we surveyed 95 surgeons from 56 domestic and 4 international institutions 
who were all members of the Congenital Heart Surgeons' Society, and we asked them to evaluate 
the range of practice regarding postoperative antibiotic prophylaxis for pediatric cardiac 
surgeries. As expected, there was a wide variation of practice related to selection and duration of 
prophylaxis. Twenty-three (24%) congenital heart surgeons responded from 16 domestic and 2 
international programs, but only three of the surgeons were familiar with the SIP project.  
Cefazolin was the most commonly chosen antibiotic for postoperative prophylaxis. Nine (60%) 
of 15 surgeons who responded stated that antibiotic prophylaxis is limited to 24 to 48 hours after 
surgery. This is consistent with ASHP, SIP, and STS recommendations. (1-3) However, a high 
percentage (40%; 6 of 15) reported continuing prophylaxis until chest tubes and all invasive lines 
(i.e., central intravenous, arterial, and intracardiac hemodynamic monitoring) were removed. 
Data from a retrospective study by Maher et al. (5) might suggest that this practice may decrease 
SSIs. However, a prospective study has demonstrated that prolonged antibiotic prophylaxis after 
48 hours does not reduce SSIs but increases antimicrobial resistance. (6) The practice of 
continuing prophylaxis for the duration of chest tube or invasive line placement has existed for 
some time and is currently not endorsed by STS. (3, 7)  
Antibiotic prophylaxis guidelines do not exist for procedures such as ventricular assist device 
(VAD) placement, cardiac extracorporeal membrane oxygenation (ECMO), and delayed sternal 
closure (DSC) cases. Infection-related morbidity and mortality in patients who receive these 
procedures is of significant concern. Use of vancomycin-containing regimens (21/42 [50%]) and 
regimens containing antimicrobials with broad gram-negative or anaerobic coverage (i.e., 
cefoxitin, ceftazidime, ceftriaxone, gentamicin, piperacillin) were commonly reported by 
surgeons for VAD, ECMO, and DSC (22/42 [52%]). The majority of respondents indicated that 
prophylaxis is continued for the entire duration of VAD placement, ECMO, and DSC procedures 
(13/15 [87%], 15/16 [94%], and 24/26 [92%], respectively). Prolonged antimicrobial exposure 
not only increases risk of infection with resistant bacteria, but potentially increases the possibility 
of fungal infection which can significantly increase mortality risk in patients receiving VAD 
support. (8) With technological advances in mechanical circulatory support devices and 
improvements in outcomes in children undergoing these procedures, a balance must be made 
between adequate antimicrobial prophylaxis duration and selection of antibiotic-resistant 
bacteria.  
Our survey demonstrated that the use of antimicrobial prophylaxis for congenital heart surgery is 
standard. However, there is wide variation in selection and duration of prophylaxis, and areas of 
discordance exist between national and organizational recommendations and current practices. 
Prolonged use of antimicrobials leads to the increased incidence of resistant enterobacteriaceae 
and enterococci. (3, 6) Pharmacists play a critical role in the appropriate use of antimicrobials, 
and can seize this opportunity to collaborate with congenital heart surgeons to develop institution 
specific protocols for postoperative antibiotic prophylaxis. The development of consensus 
recommendations for postoperative antimicrobial prophylaxis for children after cardiac surgery, 
and the concurrent design of a national database to collect and assess long-term outcomes 
associated with those recommendations may be attainable through pharmacist and surgeon 
collaboration.  
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